LX-4211
-
LX-4211
structure -
-
CAS No:
1018899-04-1
-
Formula:
C21H25ClO5S
-
Chemical Name:
LX-4211
-
Synonyms:
(2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(methylsulfanyl)tetrahydro-2-H-pyran-3,4,5-triol;CS-1853;LX4211; LX 4211; LX4211; LX 4211;LX-4211;(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(Methylthio)tetrahydro-2H-pyran-3,4,5-triol;(5S)-Methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-1-thio-beta-L-xylopyranoside;LX4211/LX-4211;LP 802034
- Categories:
-
CAS No:
Description
Sotagliflozin has been used in trials studying the treatment of Renal impairment, Hepatic Impairment, Type 1 Diabetes Mellitus, and High Level of Sugar (Glucose) in the Blood.|Sotagliflozin is an orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity. Upon oral administration, sotagliflozin binds to and blocks both SGLT1 in the gastrointestinal (GI) tract and SGLT2 in the kidneys, thereby suppressing the absorption of glucose from the GI tract and the reabsorption of glucose by the proximal tubule into the bloodstream, respectively. This decreases glucose uptake and enhances the urinary excretion of glucose, which lowers and/or normalizes blood glucose levels. SGLT1 is the primary transporter responsible for glucose absorption from the GI tract. SGLT2, a transport protein exclusively expressed in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption from tubular fluid.
LX-4211 Basic Attributes
424.94
424.94
6B4ZBS263Y
DTXSID20144314
C119623
White to off-white
A10|A - Alimentary tract and metabolism
Characteristics
1.37±0.1 g/cm3(Predicted)
607.9±55.0 °C(Predicted)
12.87±0.70(Predicted)
Store at -20°C
Safety Information
|Warning|H351 (50%): Suspected of causing cancer [Warning Carcinogenicity]|P201, P202, P260, P273, P281, P308+P313, P314, P405, and P501|Aggregated GHS information provided by 3 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Drug Information
Zynquista is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy.|Treatment of type I diabetes mellitus|Treatment of type II diabetes mellitus
Compounds that inhibit SODIUM-GLUCOSE TRANSPORTER 2. They lower blood sugar by preventing the reabsorption of glucose by the kidney, and are used in the treatment of TYPE 2 DIABETES MELLITUS. (See all compounds classified as Sodium-Glucose Transporter 2 Inhibitors.)
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
LX-4211 Use and Manufacturing
Sotagliflozin is used for the treatment of patients with type 1 diabetes mellitus.
Human drugs -> Zynquista -> EMA Drug Category|Drugs used in diabetes -> Human pharmacotherapeutic group|Human Drugs -> EU pediatric investigation plans
Recommended Suppliers of LX-4211
-
CN
5 YRS
Business licensedTrader Supplier of API,nutrition supplements,plant extract,peptide,HCGInquiryCAS No.: 1018899-04-1Grade: Pharmaceutical GradeContent: 99% -
CN
5 YRS
Business licensed Certified factoryManufactory Supplier of fine chemicals,pharmaceutical materials -
CN
1 YR
Business licensedTrader Supplier of Pharmaceutical intermediate/API, and fragrances API -
CN
5 YRS
Business licensedTrader Supplier of PVC resin,pvc paste resin,melamineInquiryCAS No.: 1018899-04-1Grade: Industrial GradeContent: 99% -
CN
5 YRS
Business licensedDistributor Supplier of API,API Intermediates,Food supplements,Electronic Intermediates,Arochemical Intermediates,Cosmetic raw meterials,Fine Chemicals
Learn More Other Chemicals
-
5'-deoxy-5'-thioinosine 5'-monophosphate
21959-63-7
-
1-(2-Deoxy-β-D-erythro-pentofuranosyl)-2(1H)-pyrimidinone
22003-30-1
-
5'-azacytidine5'-monophosphate
2226-72-4
-
Decarboxylated AdoMet Formula
22365-13-5
-
2′-Deoxy-6-thioinosine Formula
2239-64-7
-
2,2'-Anhydro-5-methyluridine Formula
22423-26-3
-
Quercetin 3-glucuronide Structure
22688-79-5
-
1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(methylamino)pyrimidin-2-one Structure
22882-02-6
-
What is Sucrose
57-50-1
-
What is C18Dihydroceramide
2304-80-5